The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Pharmacological Profile of Lurasidone, a Novel Antipsychotic Agent with Potent 5-Hydroxytryptamine 7 (5-HT7) and 5-HT1A Receptor Activity
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A SIMPLIFIED METHOD OF EVALUATING DOSE-EFFECT EXPERIMENTS
LITCHFIELD, J. T., & WILCOXON, F. (1949) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)03549-9 · Cited by 7,812
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321 · cited 1×
“Previous studies (e.g., Santarelli et al., 2003) have also suggested that 5-HT1A receptor activation mediates the effects of selective SSRI on the hippocampus neurogenesis, which is considered to underlie the anxiolyticand antidepressant-like effects of chronic administration with SSRI.”
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
Muscarinic Cholinergic Binding in Rat Brain
Yamamura, H. I., & Snyder, S. H. (1974) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.71.5.1725 · Cited by 1,203
Kroeze, W. K., Hufeisen, S. J., Popadak, B. A., Renock, S. M., Steinberg, S., Ernsberger, P., Jayathilake, K., Meltzer, H. Y., & Roth, B. L. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300027 · Cited by 801
Serotonin receptors : their key role in drugs to treat schizophrenia
Meltzer, H. Y., Li, Z., Kaneda, Y., & Ichikawa, J. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.010 · Cited by 775
The olfactory bulbectomized rat as a model of depression: An update
Kelly, J. P., Wrynn, A. S., & Leonard, B. E. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(97)00004-1 · Cited by 662
Positive and Negative Symptoms in Schizophrenia: A Critical Reappraisal
Andreasen, N. C. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810190015002 · Cited by 410
Functional, molecular and pharmacological advances in 5-HT receptor research
HEDLUND, P., & SUTCLIFFE, J. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.07.002 · Cited by 350
Improving the Treatment of Schizophrenia: Focus on Serotonin (5-HT)1A Receptors
Millan, M. J. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38982-7 · Cited by 287
5-HT7 receptor inhibition and inactivation induce antidepressantlike behavior and sleep pattern
Hedlund, P. B., Huitron-Resendiz, S., Henriksen, S. J., & Sutcliffe, J. G. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.05.012 · Cited by 281
The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent.
Moore, N. A., Tye, N. C., Axton, M. S., & Risius, F. C. (1992) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10792-1 · Cited by 278
Arnt, J. (1982) · Acta Pharmacologica et Toxicologica · doi:10.1111/j.1600-0773.1982.tb01032.x · Cited by 238
Positive and negative symptoms in schizophrenia
Rosen, W. G., Mohs, R. C., Johns, C. A., Small, N. S., Kendler, K. S., Horvath, T. B., & Davis, K. L. (1984) · Psychiatry Research · doi:10.1016/0165-1781(84)90075-1 · Cited by 238
Wesołowska, A., Nikiforuk, A., Stachowicz, K., & Tatarczyńska, E. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.04.017 · Cited by 230
Characterization and distribution of putative 5‐ht7receptors in guinea‐pig brain
To, Z. P., Bonhaus, D. W., Eglen, R. M., & Jakeman, L. B. (1995) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1995.tb16327.x · Cited by 225
Chang, R. S. L., Tran, V. T., & Snyder, S. H. (1979) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1979.tb02276.x · Cited by 224
Lurasidone in the Treatment of Acute Schizophrenia: A Double-Blind, Placebo-Controlled Trial
Nakamura, M., Ogasa, M., Guarino, J., Phillips, D., Severs, J., Cucchiaro, J., & Loebel, A. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04905 · Cited by 191
Self-citationIshiyama, T., Tokuda, K., Ishibashi, T., Ito, A., Toma, S., & Ohno, Y. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.06.058 · Cited by 165
Self-citationMice lacking 5‐HT7 receptors show specific impairments in contextual learning
Roberts, A. J., Krucker, T., Levy, C. L., Slanina, K. A., Sutcliffe, J. G., & Hedlund, P. B. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03288.x · Cited by 162
The 5-HT2C receptor and antipsychoticinduced weight gain – mechanisms and genetics
Reynolds, G. P., Hill, M. J., & Kirk, S. L. (2006) · Journal of Psychopharmacology · doi:10.1177/1359786806066040 · Cited by 160
Weight change with atypical antipsychotics in the treatment of schizophrenia
Haddad, P. M. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105058378 · Cited by 148
Lurasidone: a new drug in development for schizophrenia
Meyer, J. M., Loebel, A. D., & Schweizer, E. E. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903286388 · Cited by 141
ENOMOTO, T., ISHIBASHI, T., TOKUDA, K., Ishiyama, T., TOMA, S., & Itô, A. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.08.012 · Cited by 132
Self-citationThe 5-HT7 receptor is involved in allocentric spatial memory information processing
Sarkisyan, G., & Hedlund, P. B. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.03.011 · Cited by 125
Meneses, A. (2004) · Behavioural Brain Research · doi:10.1016/j.bbr.2004.04.026 · Cited by 116
Lieberman, J. A. (1993) · British Journal of Psychiatry · doi:10.1192/s0007125000292544 · Cited by 108
Bersani, G., Grispini, A., Marini, S., Pasini, A., Valducci, M., & Ciani, N. (1990) · Clinical Neuropharmacology · doi:10.1097/00002826-199012000-00003 · Cited by 105
Harvey, P. D., Meltzer, H. Y., Simpson, G. M., Potkin, S. G., Loebel, A. D., SIU, C. O., & Romano, S. J. (2003) · Schizophrenia Research · doi:10.1016/j.schres.2003.07.009 · Cited by 104
Sallinen, J., Höglund, I. P. J., Engström, M., Lehtimäki, J., Virtanen, R., Sirviö, J., Wurster, S., Savola, J., & Haapalinna, A. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707005 · Cited by 98
Effect of 5-HT7 antagonist SB-269970 in the modulation of working and reference memory in the rat
Gasbarri, A., Cifariello, A., Pompili, A., & Meneses, A. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.12.020 · Cited by 97
Uhlén, S., Dambrova, M., Näsman, J., Schiöth, H. B., Gu, Y., Wikberg-Matsson, A., & Wikberg, J. E. S. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01521-5 · Cited by 95
Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia
Barnes, T. R. E., & McPhillips, M. A. (1998) · International Clinical Psychopharmacology · doi:10.1097/00004850-199803003-00009 · Cited by 89
Meltzer, H. Y. (1999) · PubMed · Cited by 71
Terry, A. V., & Mahadik, S. P. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.106047 · Cited by 69
Roberts, C., Thomas, D. R., Bate, S. T., & Kew, J. N. C. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.01.010 · Cited by 67
Meltzer, H. Y. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00255-3 · Cited by 63
Hirose, A., Kato, T., Ohno, Y., Shimizu, H., Tanaka, H., Nakamura, M., & Katsube, J. (1990) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.53.321 · Cited by 60
Self-citationBourin, M., Chenu, F., Prica, C., & Hascoët, M. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1583-7 · Cited by 59
Overexpression of Alpha2C-adrenoceptors impairs water maze navigation
Björklund, M., Sirviö, J., Riekkinen, M., Sallinen, J., Scheinin, M., & Riekkinen, P. J. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00428-5 · Cited by 49
Sakamoto, H. (1998) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(98)00068-9 · Cited by 18
Ballard, M. E., Basso, A. M., Gallagher, K. B., Browman, K. E., Fox, G. B., Drescher, K. U., Groß, G., Decker, M. W., Rueter, L. E., & Zhang, M. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0577-y · Cited by 15
Cited by
Miyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W., & Lieberman, J. A. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.47 · Cited by 573
Kaar, S. J., Natesan, S., McCutcheon, R., & Howes, O. D. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107704 · Cited by 383
The role of serotonin receptors in the action of atypical antipsychotic drugs
Meltzer, H., & Massey, B. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.02.007 · Cited by 381
Loebel, A., Cucchiaro, J., Silva, R., Kroger, H., Hsu, J., Sarma, K., & Sachs, G. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13070984 · Cited by 341
Suppes, T., Silva, R., Cucchiaro, J., Mao, Y., Targum, S., Streicher, C., Pikalov, A., & Loebel, A. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15060770 · Cited by 322
Metadata
- Authors
- Ishibashi, T., Horisawa, T., Tokuda, K., Ishiyama, T., Ogasa, M., Tagashira, R., Matsumoto, K., Nishikawa, H., Ueda, Y., Toma, S., Oki, H., Tanno, N., Saji, I., Ito, A., Ohno, Y., & Nakamura, M.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2010-07
- Volume
- 334
- Issue
- 1
- Pages
- 171-181
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2137044087
- Cited by
- 438
- References
- 42
- FWCI
- 17.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.